NanoViricides Inc (NNVC)

[BonelessCat]

That absolutely is not true. I could even characterize it as partly fiction. Most development stage biotechs own the IP as a second party license and then license that to a large pharma to complete clinical trials. Many IPs are owned by university and other research centers, who then license biopharmas, who then license large pharmas to complete clinical testing, who then license manufacturing and marketing big pharmas with well-developed promotion and distribution infrastructures.

Drug IPs are not often the clean one owner structures you present, though there are some. If you want to look at what can happen when a development stage biopharma outright owns the IP, take a look at Polymedix:

PolyMedix defaults and hands over a PhII antibiotic to bankruptcy ...
www.fiercebiotech.com/story/polymedix-defaults-and.../2013-04-02?
Apr 2, 2013 - The small, struggling PolyMedix (PYMX) has thrown in the towel and handed over the company to a bankruptcy court. Just two weeks after the ...
Cellceutix Acquires PolyMedix Assets From Bankruptcy Court, Gains
cellceutix.com/cellceutix-acquires-polymedix-assets-from-bankruptcy-co...?
Sep 9, 2013 - The acquisition includes PolyMedix's flagship drug candidate Brilacidin, a first-in-class defensin-mimetic antibiotic that has completed a Phase ...

Normally the biotech you invest in owns the IP. The IP is what (you own) and invest in. Then later if successful the company licenses the IP to third parties.